Viewing Study NCT04497662



Ignite Creation Date: 2024-05-06 @ 3:00 PM
Last Modification Date: 2024-10-26 @ 1:41 PM
Study NCT ID: NCT04497662
Status: COMPLETED
Last Update Posted: 2021-05-04
First Post: 2020-07-28

Brief Title: Study to Evaluate the Safety Tolerability Pharmacokinetics and Pharmacodynamics of Single Ascending Doses of KPL-404 in Healthy Subjects
Sponsor: Kiniksa Pharmaceuticals GmbH
Organization: Kiniksa Pharmaceuticals GmbH

Study Overview

Official Title: A Phase 1 First-in-human Randomized Double-blind Placebo-controlled Study Evaluating the Safety Tolerability Pharmacokinetics and Pharmacodynamics of Single Ascending Intravenous and Subcutaneous Doses of KPL-404 in Healthy Subjects
Status: COMPLETED
Status Verified Date: 2021-05
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: Phase 1 randomized double-blind placebo-controlled first-in-human study to investigate the safety tolerability PK and PD properties of single ascending intravenous IV and subcutaneous SC doses of KPL-404 in healthy subjects
Detailed Description: This study includes 2 single ascending dose SAD parts Part A IV SAD up to 5 planned dose level cohorts and Part B SC SAD up to 3 planned dose level cohorts

Safety assessments will include adverse events AEs concomitant medications clinical laboratory vital signs 12-lead electrocardiogram and physical examination Serial blood samples for PK PD and anti-drug antibodies will be performed during each part of the study during the Treatment and Safety Evaluation Period

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: True
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None